Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 3
2001 3
2002 3
2003 4
2004 6
2005 7
2006 5
2007 6
2008 7
2009 5
2010 15
2011 19
2012 13
2013 15
2014 14
2015 11
2016 16
2017 13
2018 12
2019 8
2020 9
2021 10
2022 15
2023 13
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Results by year

Filters applied: . Clear all
Page 1
Targeting hypoxia-inducible factors with 32-134D safely and effectively treats diabetic eye disease in mice.
Zhang J, Sharma D, Dinabandhu A, Sanchez J, Applewhite B, Jee K, Deshpande M, Flores-Bellver M, Hu MW, Guo C, Salman S, Hwang Y, Anders NM, Rudek MA, Qian J, Canto-Soler MV, Semenza GL, Montaner S, Sodhi A. Zhang J, et al. Among authors: rudek ma. J Clin Invest. 2023 Jul 3;133(13):e163290. doi: 10.1172/JCI163290. J Clin Invest. 2023. PMID: 37227777 Free PMC article.
DPYD Testing: Time to Put Patient Safety First.
Baker SD, Bates SE, Brooks GA, Dahut WL, Diasio RB, El-Deiry WS, Evans WE, Figg WD, Hertz DL, Hicks JK, Kamath S, Kasi PM, Knepper TC, McLeod HL, O'Donnell PH, Relling MV, Rudek MA, Sissung TM, Smith DM, Sparreboom A, Swain SM, Walko CM. Baker SD, et al. Among authors: rudek ma. J Clin Oncol. 2023 May 20;41(15):2701-2705. doi: 10.1200/JCO.22.02364. Epub 2023 Feb 23. J Clin Oncol. 2023. PMID: 36821823 No abstract available.
Six-month effective treatment of corneal graft rejection.
Meng T, Zheng J, Chen M, Zhao Y, Sudarjat H, M R AA, Kulkarni V, Oh Y, Xia S, Ding Z, Han H, Anders N, Rudek MA, Chow W, Stark W, Ensign LM, Hanes J, Xu Q. Meng T, et al. Among authors: rudek ma. Sci Adv. 2023 Mar 22;9(12):eadf4608. doi: 10.1126/sciadv.adf4608. Epub 2023 Mar 22. Sci Adv. 2023. PMID: 36947612 Free PMC article.
Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial.
Rubinstein PG, Moore PC, Bimali M, Lee JY, Rudek MA, Chadburn A, Ratner L, Henry DH, Cesarman E, DeMarco CE, Costagliola D, Taoufik Y, Ramos JC, Sharon E, Reid EG, Ambinder RF, Mitsuyasu R, Mounier N, Besson C, Noy A; AIDS Malignancy Consortium; Lymphoma Study Association. Rubinstein PG, et al. Among authors: rudek ma. Lancet Haematol. 2023 Aug;10(8):e624-e632. doi: 10.1016/S2352-3026(23)00157-6. Lancet Haematol. 2023. PMID: 37532416 Clinical Trial.
Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies.
Shafer D, Kagan AB, Rudek MA, Kmieciak M, Tombes MB, Shrader E, Bandyopadhyay D, Hudson D, Sankala H, Weir C, Lancet JE, Grant S. Shafer D, et al. Among authors: rudek ma. Cancer Chemother Pharmacol. 2023 Mar;91(3):281-290. doi: 10.1007/s00280-023-04511-0. Epub 2023 Mar 2. Cancer Chemother Pharmacol. 2023. PMID: 36864346 Free PMC article. Clinical Trial.
199 results